CIM
SUPN icon

Chiron Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Chiron Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,058
Closed -$145K – 171
2022
Q4 		$145K Hold
4,058
– – 0.03% 96
2022
Q3 		$137K Buy
+4,058
New +$132K 0.03% 108

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Chiron Investment Management's SUPN Position: Q1 2023 in Review

Chiron Investment Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2023, closing a stake of 4,058 shares — an estimated $145K sold.

Chiron Investment Management first reported a position in SUPN in Q3 2022 and held it in 2 quarters. The position peaked at $145K in Q4 2022. 258 funds tracked by Wall St. Rank hold SUPN as of Q1 2023.

  • Chiron Investment Management reported no remaining Supernus Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Chiron Investment Management sold 4,058 Supernus Pharmaceuticals shares in Q1 2023, an estimated $145K.
  • Chiron Investment Management first reported a position in Supernus Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Chiron Investment Management's Supernus Pharmaceuticals position peaked at $145K in Q4 2022.
  • 258 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2023.

Based on Chiron Investment Management's 13F filing for Q1 2023, filed 15 May 2023.